The role of TP53 mutations in oral cancer: molecular mechanisms and prognostic implications
TP53 mutations are strongly associated with advanced tumor stage, lymph node metastasis, therapy resistance, and poor prognosis in oral squamous cell carcinoma.
A comprehensive review highlights how TP53 mutations contribute to oral cancer development, treatment resistance, and poor patient outcomes. The study summarizes emerging therapeutic approaches, including mutant p53 reactivation, synthetic lethality, and immunotherapy‑based strategies, providing new perspectives for precision medicine in oral cancer.
TP53 mutations are one of the most frequent genetic alterations in oral cancer, driving tumor progression and conferring resistance to conventional therapies. Identifying TP53 status can inform risk stratification, prognosis, and the development of targeted treatments that may improve survival and reduce recurrence.
Bizonyítékszint: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Kapcsolódó jelek
- A case report of advanced small intestinal stromal tumor with KIT gene mutation and BRCA2 deletion after multi-line treatments
- Review of Genomic Testing and SDH Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST
- Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives
- Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
- UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)